FDA Grants BTD to T-DXd in HER2+ BC With Residual Invasive Disease Post NAT

Pimicotinib Earns Approval in China for Tenosynovial Giant Cell Tumors

Videos MATTERHORN Trial Design and DFLOT Adoption: Integrating Immunotherapy Into Perioperative Practice
Trending Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Do you need to fulfill your end of the year CE credit needs? SCOPE of Pain education is free!
 
SCOPE of Pain Podcast Series SCOPE of Pain supplemental trainings are designed as follow up trainings after the free 2-module online activity, a 6-Part Podcast series, or a live or archived webinar have been completed. These in-depth supplemental trainings focus on: Accreditation These activities have been approved for AMA PRA Category 1 Credit™. Check the scopeofpain.org website for more accreditation details on each prof. SCOPE of Pain is provided by:
Boston University Chobanian & Avedisian School of Medicine in partnership with the Federation of State Medical Boards.

Disclosure of support:
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA
The MARIPOSA update series explores the evolving treatment landscape for EGFR-mutant non–small cell lung cancer (NSCLC), highlighting how the amivantamab plus lazertinib combination outperforms osimertinib as a first-line therapy. Through updated analyses from ESMO 2025, it demonstrates that this dual EGFR-MET targeting approach significantly reduces mechanisms of acquired resistance—especially MET amplification and secondary EGFR mutations—resulting in longer progression-free and overall survival. The findings reinforce the biologic rationale for early combination therapy, reduced mutational heterogeneity, and the potential to reshape long-term outcomes for patients with EGFR-mutant NSCLC

Featured Video Interpreting MET Amplification and Heterogeneity in EGFR Resistance
Demonstrates that longer amivantamab exposure further reduces the emergence of MET and EGFR mutations.
 

FACE-OFF: Low-Risk MDS SOHO 2025
Panelists discuss how to optimize treatment approaches for patients with lower-risk myelodysplastic syndrome through a competitive debate format covering luspatercept vs erythropoiesis-stimulating agents as first-line therapy, management of super-responders, timing of treatment initiation, and real-world evidence from recent clinical trials including COMMANDS, MEDALIST, and IMerge.

Featured Video
 

Free On-Demand Opioid Analgesic REMS-Compliant CPE and CME!
Pain Management CE
Opioid REMS Education: A Patient-Centered Pain Management Guide for the Interprofessional Team
This educational activity is highly relevant to interprofessional clinicians involved in the care of patients receiving opioid analgesic therapy, nonpharmacologic therapies, and non-opioid therapies for pain in hospitals, health systems and ambulatory care centers to appropriately manage pain and support the safe use of medication therapy for the treatment of pain.  
We invite you to share this free educational activity with your colleagues.

Featuring...
















Target Audience



Learning Objectives  








Agenda















Accredited for CPE















Other parts of the Initiative...

Nogapendekin Alfa Combo Shows Survival Benefits in BCG-Unresponsive NMIBC

FDA Grants Fast Track Designation to GPC3x4-1BB Bispecific Antibody in HCC

Videos Trending

Education Alert
An Expert Discussion of Key New Data in CLL and MCL: How May It Impact Future Practice?
0.50 CME / CE / ABIM MOC
Are you up to date with recent data in patients with CLL and MCL? Listen to our experts for insight on trial results

Treatment Strategies for the Management of LS-SCLC and NSCLC
FACE-OFF: Team Phantoms vs Team Accelerators: Treatment Strategies for the Management of LS-SCLC and NSCLC

Featured Video Clinical Scenario: When Would You Offer LCT?
Panelists discuss how the decision to offer local consolidative therapy in oligometastatic non–small cell lung cancer depends on multiple factors including PET scan activity at 6 months, the feasibility of rendering patients with no evidence of disease, multidisciplinary collaboration, and the emerging need for a “third box” treatment category beyond curative and palliative intent that addresses preemptive strikes against limited progressive sites to prolong survival.